R&D News | pharmaphorum

News

Shortly after reporting weaker sales growth for its injectable GLP-1 drugs, Novo Nordisk has new data to help it stake a claim to the oral market.

News

The battle for obesity drug developer Metsera rumbles on, with Pfizer reported to have now matched Novo Nordisk's $10 billion offer.

News

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

Two new reports suggest the UK is seeing an exodus of skilled STEM workers to other countries, placing the country's economic future at risk.

News

Metsera has now received new takeover bids from both Pfizer and Novo Nordisk, and has plumped for a sweetened $10bn offer from the latter.

News

The ESSENCE trial of Sarepta's Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.